Sight Sciences to Debut the OMNI Ultra® Surgical System, the Latest Technology Advancement from the Pioneers of Ab Interno Canaloplasty, at the 2026 American Academy of Ophthalmology (AAO) Annual Meeting

Sight Sciences (SGHT) announced commercial availability of the OMNI Ultra Surgical System, the latest generation of its glaucoma surgery platform.

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

Sight Sciences (SGHT) announced commercial availability of the OMNI Ultra Surgical System, the latest generation of its glaucoma surgery platform. The implant-free device enables single-pass canaloplasty followed by trabeculotomy, procedures that address resistance in the eye’s fluid drainage pathway. It can be used alone or with cataract surgery in adults with primary open-angle glaucoma.

OMNI Ultra will be featured at the AAO annual meeting, October 9–12 in New Orleans. Sight Sciences will also preview Clearance Assistant Plus, a tool for meibomian gland expression and eyelid debridement used with the TearCare System.

Historical Context

1 past event · Latest: Aug 04

1 event

Aug 04
FDA clearance

24h Move

-1.6%

FDA cleared the same OMNI Ultra system for canaloplasty followed by trabeculotomy before commercial availability.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

ab interno canaloplasty, minimally invasive glaucoma surgery (migs), trabeculotomy, intraocular pressure (iop), +2 more

6 terms

ab interno canaloplasty medical

"an expansion of its pioneering ab interno canaloplasty platform"

A minimally invasive eye surgery for glaucoma that restores the eye’s natural fluid outflow by opening and dilating Schlemm’s canal from inside the eye, typically using a tiny catheter and a tensioning suture or similar device. Think of it like threading and widening a clogged drainpipe from the inside to let fluid flow more freely; it matters to investors because adoption, device suppliers, procedure volumes and reimbursement affect companies in ophthalmic devices and surgical services.

minimally invasive glaucoma surgery (migs) medical

"implant-free, minimally invasive glaucoma surgery (MIGS) category"

Minimally invasive glaucoma surgery (MIGS) is a group of surgical techniques and small implantable devices designed to lower intraocular pressure by improving fluid outflow from the eye through micro‑incisions and minimal tissue disruption. MIGS procedures are performed through small openings, often at the time of cataract surgery, and aim for faster recovery and lower complication rates than traditional glaucoma surgeries; however, they generally produce more modest pressure reduction and are most commonly used for mild-to-moderate glaucoma rather than advanced disease.

trabeculotomy medical

"single pass canaloplasty followed by trabeculotomy"

A trabeculotomy is a surgical procedure that creates an opening in the eye’s natural drainage tissue to help fluid escape and lower elevated pressure caused by glaucoma; think of it as unblocking a clogged sink so fluid can flow out. Investors care because the procedure drives demand for surgical devices, implants and follow-up treatments, and its safety, effectiveness, and reimbursement profile influence adoption rates and the commercial prospects of companies in eye care.

intraocular pressure (iop) medical

"designed to reduce intraocular pressure (IOP)"

Intraocular pressure (IOP) is the fluid pressure inside the eye, like the air pressure inside a tire that keeps the eye’s shape and function stable. IOP matters to investors because persistently high pressure is the main risk factor for glaucoma and other vision problems, so IOP readings drive demand for medicines, devices and clinical trials, influence regulatory decisions, and can materially affect a healthcare company’s revenue outlook.

schlemm’s canal medical

"Accesses the entire circumference of Schlemm’s canal"

A circular channel in the white part of the eye that collects aqueous humor (the fluid made inside the eye) from the trabecular meshwork and delivers it into the eye’s venous circulation. It acts as a primary outflow pathway that helps regulate intraocular pressure; if the canal is blocked or dysfunctional, fluid drainage is reduced and eye pressure can rise.

viscodilation medical

"automatic and predictable viscodilation of Schlemm’s canal"

A surgical technique that uses a viscous, gel-like fluid (a viscoelastic) to mechanically widen a small channel, vessel or lumen so fluid can flow more freely. The surgeon injects the viscoelastic into the target structure to push its walls apart and reduce collapse or obstruction; in ophthalmology this is commonly used to dilate Schlemm’s canal and improve aqueous outflow in glaucoma procedures. The effect is mechanical and often temporary unless combined with other steps that modify tissue or maintain patency.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

10/01/2026 - 07:05 AM

MENLO PARK, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences, or the Company), an eyecare company focused on developing and commercializing innovative, interventional technologies intended to transform eye care and improve patients’ lives, today announced the commercial availability of the OMNI^® Ultra Surgical System (OMNI Ultra), an expansion of its pioneering ab interno canaloplasty platform. The new technology will be featured at this year’s American Academy of Ophthalmology (AAO) annual meeting held on October 9-12 in New Orleans, Louisiana.

“Sight Sciences has not only been a thought leader in the advancement of the implant-free interventional glaucoma category, they have gone one step further with their commitment to continued innovation,” said Dr. Zarmeena Vendal, Cataract and Glaucoma Surgeon, Owner at Westlake Eye Specialists, and OMNI Ultra pre-launch user. “The OMNI Ultra is the latest example of this commitment. I have relied on the OMNI Surgical System for 8 years now and can still appreciate how OMNI Ultra builds on a proven technology platform with even more versatility and procedural flexibility. This addresses the needs of a broader range of surgeons, and this is a key to moving interventional glaucoma forward.”

As the innovator of comprehensive ab interno canaloplasty intervention, Sight Sciences has been setting the standard for interventional glaucoma since the first expanded FDA glaucoma clearance of its OMNI technology platform in 2021. OMNI Ultra represents the latest generation of the Company’s OMNI product family, elevating the versatility, confidence, and procedural control of the OMNI Surgical System while maintaining its proven safety profile and efficacy. The Company created the implant-free, minimally invasive glaucoma surgery (MIGS) category and introduced the very first FDA cleared device for performing ab interno canaloplasty. OMNI Ultra, the next generation technology, enables single pass canaloplasty followed by trabeculotomy while also featuring TruSync™ Plus technology and enhanced catheter visualization. OMNI Ultra is designed to reduce intraocular pressure (IOP) by addressing all three known areas of resistance within the conventional aqueous outflow pathway: the trabecular meshwork, Schlemm’s canal, and the collector channels. The technology can be used in a standalone procedure or in combination with cataract surgery in adult patients with primary open-angle glaucoma.

Key Features of OMNI Ultra

Comprehensive implant-free intervention: Addresses all three known areas of outflow resistance through a single, clear corneal microincision without leaving an implant behind.
Single pass canaloplasty: Accesses the entire circumference of Schlemm’s canal with a single pass for canaloplasty followed by trabeculotomy.
TruSync Plus technology: Provides automatic and predictable viscodilation of Schlemm’s canal upon both advancement and retraction of the microcatheter throughout the canaloplasty procedure.
Expanded treatment versatility: Preserves the flexibility surgeons value in the OMNI platform, enabling customized treatment across varying disease severities and surgical settings while supporting enhanced catheter visualization to help surgeons confidently assess and tailor treatment delivery.

“AAO represents an important opportunity to showcase our enhanced product portfolio for physicians and industry leaders, and we are excited to launch OMNI Ultra at the meeting this year,” said Paul Badawi, CEO and co-founder of Sight Sciences. “At Sight Sciences, we remain steadfast in our mission to equip eyecare providers with versatile, efficacious technologies that address the root cause of disease through procedural intervention. The launch of OMNI Ultra, which was expertly designed through direct collaboration with our surgeon customers, reflects our deep commitment to advancing our comprehensive, implant-free, interventional glaucoma platform.”

Beyond Interventional Glaucoma and within its Interventional Dry Eye business, Sight Sciences will also preview the new Clearance Assistant Plus™ at AAO, a dual-action tool designed for both meibomian gland expression and eyelid debridement for use with the TearCare^® System.

Experience Sight Sciences and OMNI Ultra at AAO 2026
Join us in celebrating the launch of OMNI Ultra and our partners at the AAO annual meeting in New Orleans, where Sight Sciences will be hosting the following events:

ASOA Live! IG Dinner Series (Oct. 8, 6:30 pm – 8:30 pm): Tableau, 616 St. Peter Street for an engaging, case-based discussion exploring the real-world adoption of interventional glaucoma across three distinct practices.
TearCare Clearance Experience Sessions (Oct. 10 and Oct. 11, 9:00 am – 10:00 am; 12:00 pm – 1:00 pm; 3:00 pm – 4:00 pm): See a live TearCare demonstration at Booth #1237, then hear from peers in these exclusive sessions sharing real-world insights on integrating TearCare into clinical practice.
IX (Intersection of Intervention) EYEcon Appreciation Reception (Oct. 10, 6:00 pm – 8:00 pm): Sazerac House, 101 Magazine Street for a special evening dedicated to celebrating our partnership with our IX EYEcons, recognizing your impact, and previewing our newest innovations. RSVP here for the IX EYEcon Appreciation Reception.

To learn more about our full list of events, visit the link here. Additionally, attendees are invited to visit Booth #1237 during exhibit hours to experience the latest innovations in our portfolio.

About the OMNI Ultra Surgical System
The OMNI^® Ultra Surgical System is a handheld, single-use therapeutic device for MIGS. The technology is designed to enable comprehensive intervention within the eye’s conventional aqueous outflow pathway through canaloplasty and trabeculotomy, addressing the trabecular meshwork, Schlemm’s canal, and the collector channels through a single clear corneal microincision.

The OMNI Ultra Surgical System is indicated for canaloplasty (microcatheterization and viscodilation of Schlemm’s canal) followed by trabeculotomy (cutting of the trabecular meshwork) to reduce intraocular pressure in adult patients with primary open-angle glaucoma.

About the TearCare System
The TearCare^® System is designed to address meibomian gland dysfunction through precisely controlled, targeted thermal energy delivered directly to the eyelids while preserving natural blinking. Its proprietary SmartLids^® technology maintains a calibrated therapeutic gland obstruction melting temperature within the meibomian glands of all four eyelids, helping soften obstructive meibum and, when combined with clinician-directed manual expression, effectively clear gland obstructions and improve meibomian gland function.

The TearCare System is indicated in the United States for thermal-activated gland expression therapy that improves meibomian gland function in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD), when used in conjunction with manual expression of the meibomian glands.

About Sight Sciences
Sight Sciences is an eyecare technology company focused on developing and commercializing innovative and interventional solutions intended to transform care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s OMNI^® Surgical System is implant-free, minimally invasive glaucoma surgery technologies indicated in the United States to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The OMNI Surgical System is CE Marked for the catheterization and transluminal viscodilation of Schlemm’s canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma. Glaucoma is the world’s leading cause of irreversible blindness. The SION^® Surgical System is a bladeless, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The Company’s TearCare^® System is 510(k) cleared in the United States for thermal-activated gland expression therapy that improves meibomian gland function in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD), when used in conjunction with manual expression of the meibomian glands, enabling clearance of gland obstructions by physicians to address the leading cause of dry eye disease. Visit www.sightsciences.com for more information.

Sight Sciences, TearCare, and SmartLids are trademarks of Sight Sciences registered in the United States. OMNI, SION, and the Sight Sciences logo are trademarks of Sight Sciences registered in the United States, European Union and other territories. TruSync and Clearance Assistant Plus are trademarks of Sight Sciences.

Investor contact:
Philip Taylor
Gilmartin Group
415.937.5406
Investor.Relations@Sightsciences.com

Media contact:
pr@SightSciences.com